Brand Name Giants Keep Good Times Rolling Thanks to Series of Price Hikes on American Patients

New fourth quarter earnings reports released this week from brand name giants Eli Lilly, Roche, Novartis and Pfizer demonstrate that out-of-control prescription drug prices paired with repeated price hikes continue to support big time profits for Big Pharma. All four drug companies boasted high sales off of blockbuster drugs for the final quarter of 2019.

Eli Lilly bested Wall Street expectations after hiking prices on blockbuster on a diabetes treatment.

Roche bested sales thanks to strong sales of cancer and multiple sclerosis drugs.

Novartis kept the good times rolling by growing sales this quarter.

Pfizer also reported strong earnings led by increased sales of new drugs.

And while price-gouging American patients is keeping profits high for Pfizer, the introduction of a generic version to the company’s block buster pain medication Lyrica demonstrates how increased competition in the marketplace is working elsewhere to lower prices.

Sales of Lyrica dipped 67 percent this quarter after the drug began facing generic competition last year — providing patients with more affordable alternatives.

The strong earnings reports come as all four companies have continued to hike prices on their prescription drugs.

Eli Lilly




These most recent earnings reports prove yet again that Big Pharma is more concerned with profits not patients.

Stay tuned as we continue to monitor Q4 earnings announcements from brand name drug makers over the coming weeks.


Sign-up for updates

  • This field is for validation purposes and should be left unchanged.